Choose Site

Press Release

Morgan Lewis Advises uniQure on Acquisition of Corlieve Therapeutics

June 22, 2021

LONDON, June 22, 2021: Morgan Lewis has advised uniQure N.V., a leading gene therapy company, on its agreement to acquire Corlieve Therapeutics, a private French biotech company. Corlieve’s lead program seeks to employ miRNA silencing technology to treat patients with temporal lobe epilepsy. 

The cross-border Morgan Lewis team advising uniQure included partners Tim Corbett, Suzanne Filippi, Louis Beardell, Robert Smyth and Olivier Chambord, and associates Allison Soilihi, Xavier Martin and Deping Chai.

For more, read uniQure’s announcement.